Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction

(QuANTUM-R). An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive, (n.d.). https://clinicaltrials.gov/ct2/show/NCT02039726 (Accessed 12 January 2017). Gary Gilliland, 2002, The roles of FLT3 in hematopoiesis and leukemia, Blood, 100, 1532, 10.1182/blood-2002-02-0492 Small, 2006, FLT3 mutations: biology and treatment, Hematology Am. Soc. Hematol. Educ. Program, 178, 10.1182/asheducation-2006.1.178 Zarrinkar, 2009, AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML), Blood, 114, 2984, 10.1182/blood-2009-05-222034 Kampa-Schittenhelm, 2013, Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms, Mol. Cancer, 12, 19, 10.1186/1476-4598-12-19 Cortes, 2013, Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status, J. Clin. Oncol., 31, 3681, 10.1200/JCO.2013.48.8783 Li, 2015, Absorption, metabolism, and excretion of quizartinib (AC220), a FLT3 tyrosine kinase inhibitor for treatment of acute myeloid leukemia, in healthy male volunteers, Blood, 120, 4327, 10.1182/blood.V120.21.4327.4327 Sanga, 2016, An open-label, single-dose, phase I study of the absorption, metabolism, and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia, Xenobiotica, 1 Chao, 2009, Identification of N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo-[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor, J. Med. Chem., 52, 7808, 10.1021/jm9007533 European Medicine Agency, Guideline on bioanalytical method validation, 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf (Accessed 10 May 2016). Centre for Drug Evaluation and research of the U.S. Department of Health and Human Services Food and Drug Administration, Guidance for Industry Bioanalytical Method Validation, 2001. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064964.htm (Accessed 10 May 2016). Rood, 2016, Liquid chromatography–tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma, J. Chromatogr. B, 1031, 80, 10.1016/j.jchromb.2016.07.037 Kollipara, 2011, International guidelines for bioanalytical method validation: a comparison and discussion on current scenario, Chromatographia, 73, 201, 10.1007/s10337-010-1869-2 Rocci, 2007, Confirmatory reanalysis of incurred bioanalytical samples, AAPS J., 9, E336, 10.1208/aapsj0903040